Inhibition of Testicular Androgen Biosynthesis by Chronic Administration of a Potent LHRH Agonist in Adult Men

References

• Ahmed S R., Brooman P JC, Shalet S M., Howell A, Blacklock V J., Richards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: Clincial response and hormonal mechanisms. Lancet 1983; 2: 415–418
   PubMed Web of Science ®Google Scholar
• Akhtar F B., Marshall G R., Wickings E J., Nieschlag E. Reversible induction of azoospermia in rhesus monkeys by constant infusion of a gonadotropin-releasing hormone agonist using osmotic minipumps. J Clin Endocrinol Metab 1983; 56: 534–540
   Google Scholar
• Asch R H., Siler-Khodr T M., Smith C G., Schally A V. Luteolytic effects of D-Trp6 -luteinizing hormone-releasing hormone in the rhesus monkey (Maccaca mulatta). J Clin Endocrinol Metab 1981; 52: 565–571
   Google Scholar
• Auclair C, Kelly P A., Labrie F, Coy D H., Schally A V. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropin. Biochem Biophys Res Commun 1977; 76: 855–862
   PubMed Web of Science ®Google Scholar
• Bélanger A, Auclair C, Ferland L, Labrie F. Time-course of the effects of treatment with a potent LHRH agonist on testicular steroidogenesis and gondaotropin receptor levels in the adult rat. J Steroid Biochem 1980; 13: 191–196
   PubMedGoogle Scholar
• Bélanger A, Auclair C, Séguin C, Kelly P A., Labrie F. Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: Role of prolactin. Mol Cell Endocrinol 1979; 13: 47–53
   PubMed Web of Science ®Google Scholar
• Bergquist C, Nillius S J., Bergh T, Skarin G, Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol 1979; 91: 601–608
   PubMedGoogle Scholar
• Bhasin S, Heber D, Steiner B, Peterson M, Blaisch B, Campfield L A., Swerdloff R S. Hormonal effects of GnRH agonist in the human male. II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist. Clin Endocrinol 1984; 20: 119–128
   Google Scholar
• Borgman V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R. Sustained suppression of testosterone production by the leutinizing hormone-releasing hormone agonist Buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet 1982; 1: 1097–1099
   Google Scholar
• Borgman V, Nagel R, Al-Abadi H, Schmidt-Gollwitzer M. Treatment of prostatic cancer with LHRH analogues. Prostate 1983; 4: 553–568
   Google Scholar
• Bourne G A., Regiani S, Payne A H., Marshall J C. Testicular GnRH receptors: Characterization and localisation on interstitial tissue. J Clin Endocrinol Metab 1980; 51: 407–409
   Google Scholar
• Catt K H., Baukal A J., Davies T F., Dufau M L. Luteinizing hormone-releasing hormone-induced regulation of gonadotropin and prolactin receptors in the rat testis. Endocrinology 1979; 104: 17–25
   PubMed Web of Science ®Google Scholar
• Clayton R N., Catt K J. Gonadotropin-releasing hormone receptors characterization, physiological regulation and relationship to reproductive function. Endocr Rev 1981; 2: 186–209
   PubMed Web of Science ®Google Scholar
• Clayton R N., Huhtaniemi I T. Absence of gonadotropin-releasing hormone receptors in human gonadal tissue. Nature 1982; 299: 56–59
   PubMed Web of Science ®Google Scholar
• Comite F, Hench K, McNemar A, Dwyer A. LHRH analog therapy in 15 children with true precocious puberty: Effect on somatic growth and bone maturation. Program of the 64th Annual Meeting of the Endocrin Society, San Francisco, CA, 1982; 153, Abstr 293
   Google Scholar
• Corbin A. From contraception to cancer: A review of the therapeutic applications of LHRH analogues as antitumour agents. Yale J Biol Med 1982; 55: 27–47
   PubMed Web of Science ®Google Scholar
• Crowley W F., Vale W W., Rivier J, McArthur J W. LHRH in hypogonadotropic hypogonadism. LHRH Peptides ad Female and Male Contraceptives, G I. Zatuchni, J D. Shelton, J J. Sciarra. PARFR Series on Fertility Regulation, Harper & Row, Philadelphia 1981; 321–333
   Google Scholar
• Doelle G C., Alexander A N., Evans R M., Linde R, Rivier J, Vale W, Rabin D. Combined treatment with an LHRH agonist and testosterone in man. J Androl 1983; 4: 298–302
   PubMedGoogle Scholar
• Doelle G C., Evans R M., Alexander A N., Rabin D. The pituitary gonadotroph is rapidly desensitized during LHRH agonist treatment but the Leydig cell retains its responsiveness to exogenous hCG. Program of the 65th Annual Meeting of the Endocrine Society, San Antonio, TX, 1983; 363, Abstr 1131
   Google Scholar
• Evans R M., Doelle G C., Alexander A N., Uderman H D., Rabin D. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men. J Clin Endocrinol Metab 1984; 58: 862–867
   Google Scholar
• Evans R M., Doelle G C., Lindner J, Bradley V, Rabin D. A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man. J Clin Invest 1984; 73: 262–266
   PubMed Web of Science ®Google Scholar
• Evans R M., Doelle G C., Lindner J, Rabin D. Evidence that LHRH agonist analogs modify bioactivity and chromatographic behavior of luteinizing hormone. Program of the 65th Annual Meeting of the Endocrine Society, San Antonio, TX, 1983; 111, Abstr 124
   Google Scholar
• Faure N, Labrie F, Bélanger A, Lemay A, Raynaud J P., Van der Ohe M. Sensitivity of gonadotropin and gonadal steroid responses to single intranasal administration of an LHRH agonist (HOE-766) in young normal adult men. J Endocrinol Invest 1982; 5: 355–360
   Google Scholar
• Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B, Robert G. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertil Steril 1982; 37: 416–424
   Google Scholar
• Faure N, Lemay A, Laroche B, Robert G, Plante R, Jean C, Fazekas A TA. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 1983; 4: 227–251
   Google Scholar
• Faure N, Lemay A, Laroche B, Robert G, Plante R, Thabet M, Roy R, Jean C, Fazekas A TA. Clinical experience (up to 40 months) with the LHRH agonist Buserelin in the therapeutic approach of prostatic cancer. LH-RH and Its Analogs, Fertility and Antifertility Aspects, W De Gruyter, Berlin, New York 1983
   Google Scholar
• Glode L M., Robinson J, Gould S F. Protection from cycle phosphamide-induced testicular damage by an analogue of gonadotropin releasing hormone. Lancet 1981; 1: 1132–1134
   PubMed Web of Science ®Google Scholar
• Happ J, Scholz P, Weber T, Cordes U, Schramm P, Neubauer M, Beyer J. Gonadotropin secretion in eugonadotropic human males and post-menopausal females under long-term application of a potent analogue of gonadotropin-releasing hormone. Fertil Steril 1978; 30: 674–678
   Google Scholar
• Happ J, Sennerich T, Krause U, Beyer J. Pernasal gonadarelin (GnRH) analog therapy in a boy with early puberty. Neuroendocrinol Lett 1981; 3: 255–260
   Google Scholar
• Heber D, Steiner B, Rajfer J. The pituitary gland: Primary site of action gonadotropin-releasing hormone agonists in the human male. Program of the 65th Annual Meeting of the Endocrine Society, San Antonio, TX, 1983; 81, Abstr 4
   Google Scholar
• Heber D, Swerdloff R S. Male contraception. Synergism of gonadotropin-releasing hormone analog and testosterone in suppressing gonadotropin. Science 1980; 209: 936–938
   PubMedGoogle Scholar
• Hsueh A JW, Dufau M L., Catt K J. Regulation of luteinizing hormone receptors in testicular interstitial cells by gonadotropin. Biochem Biophys Res Commun 1976; 72: 1145–1152
   PubMed Web of Science ®Google Scholar
• Jacobi G H., Wenderoth U K. Gonadotropin-releasing hormone analogues for prostate cancer: Untoward side-effects of high dose regimens acquire a therapeutical dimension. Eur Urol 1982; 8: 129–134
   PubMed Web of Science ®Google Scholar
• Kelly S, Labrie F, Dupont A. Loss of LH bioactivity in men treated with an LHRH agonist and an antiandrogen. Program of the 65th Annual Meeting of the Endocrine Society, San Antonio, TX, 1983; 81, Abstract 3
   Google Scholar
• Klugo R C., Farah R N., Cerny J C. Bilateral orchiectomy for carcinoma of the prostate. Urology 1981; 17: 49–50
   Google Scholar
• Labrie F, Auclair C, Cusan L, Kelly P A., Pelletier G, Ferland L. Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. In: Endocrine Approach to Male Contraception. Int J Androl (Suppl 2) 1978; 303–318
   Google Scholar
• Labrie F, Dupont A, Bélanger A, Cusan L, Lacourciére Y, Monfette G, Laberge J G., Emond J P., Fazekas A TA, Raynaud J P., Husson J M. New hormonal therapy in prostatic combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5: 267–275
   PubMed Web of Science ®Google Scholar
• Lefebvre F A., Reeves J J., Séguin C, Massicotte J, Labrie F. Specific binding of a potent LHRH agonist in rat testis. Mol Cell Endocrinol 1980; 20: 127–134
   Google Scholar
• Linde R, Doelle G C., Alexander N, Kirchner F, Vale W, Rivier J, Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent GnRH agonist in normal men. N Engl J Med 1981; 305: 663–667
   PubMed Web of Science ®Google Scholar
• Mansfield M J., Beardsworth D E., Loughlin J S., Crawford J D., Bode H H., Rivier J, Vale W, Kushner D C., Crigler J F., Crowley W F., Jr. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. N Engl J Med 1983; 300: 1286–1290
   Google Scholar
• Nieschlag E, Cuppers H J., Wiegelmann W, Wickings E J. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 1976; 7: 138–145
   PubMed Web of Science ®Google Scholar
• Pescovitz O H., Comite F, Cassorla F, Dwyer A J., Poth M A., Sperling M A., Hench K, McNemar A, Skerda M, Loriaux D L., Cutler G B. True precocious puberty complicating congenital adrenal hyperplasia: Treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1984; 58: 857–861
   Google Scholar
• Puri C P., Csapo I A. Evaluation of antifertility effects of LHRH analogs in the guinea pig. LHRH as Female and Male Contraceptives, G I. Zatuchni, J D. Shelton, J J. Sciarra. Harper & Row, Philadelphia 1981; 126–133
   Google Scholar
• Raynaud J P., Azadian-Boulanger G, Bonne C, Perronet J, Sakiz E. Present trends in antiandrogen research. Androgens and Antiandrogens, L Martini, M Motta. Raven, New York 1977; 281–293
   Google Scholar
• Redding T W., Schally A V. Inhibiton of growth of squamous cell prostate carcinoma in rats treated with D-Trp6-LHRH. Fed Proc 1981; 40: 433
   Google Scholar
• Redding T W., Schally A V. Inhibition of prostate tumour growth in two rat models by chronic administration of D-Trp6 analogues of LHRH. Proc Natl Acad Sci USA 1981; 78: 6509–6512
   PubMed Web of Science ®Google Scholar
• Rivier C, Rivier J, Vale W. Chronic effects of (D-Trp6-Pro9 NET) LHR factor on reproductive processes in the male rat. Endocrinology 1979; 105: 1191–1201
   Google Scholar
• Sandow J. Gonadotropic and antigonade actions of LHRH analogues. Neuroendocrine Perspectives, Mueller MacLeod, 1982; Vol I: 339–395
   Google Scholar
• Sandow J. Clinical applications of LHRH and its analogues. Clin Endocrinol 1983; 18: 571–592
   PubMed Web of Science ®Google Scholar
• Sandow J, Von Rechenberg W, Baeder C. Antifertility effects of an LHRH analogue in male rats and dogs. Int J Fertil 1980; 25: 213–221
   PubMedGoogle Scholar
• Sandow J, Von Rechenberg W, Jevzabek G, Stoel W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril 1978; 30: 205–209
   PubMedGoogle Scholar
• Sandow J, Von Rechenberg W, Koning W, Hahn M, Jerzabek G, Frazer H. Physiological studies with highly active analogues of LHR. Hypothalamic Hormones: Chemistry, Physiology and Clinical Applications, D Gupta, W Voelter. Verlag Chemie-Weinheim, New York 1978; 307–326
   Google Scholar
• Sanford E J., Paulson D F., Rohner T J., Drago J R., Santen R J., Bardin C W. The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 1977; 118: 1019–1021
   PubMed Web of Science ®Google Scholar
• Santen R J., Warner B, Smith J. Use of gonadotropin releasing hormone agonist analogs for treatment of human prostatic cancer. LHRH and Its Analogs, B H. Vickery, J J. Nestor, E SE Hafez. MTP Press, Lancaster 1985
   Google Scholar
• Schaison G, Brailly S, Vuagnat P, Bouchard P, Milgram E. Absence of a direct inhibitory effect of the GnRH agonist D-Ser(TBU)6-des-Gly-NH210 GnRH ethylamide (Buserelin) or testicular steroidogenesis in men. J Clin Endocrinol Metab 1984; 58: 885–888
   Google Scholar
• Sharpe R M., Fraser H M. Leydig cells-receptors for LHRH and its agonists and their modulation by administration or deprivation of the releasing hormone. Biochem Biophys Res Commun 1980; 95: 256–262
   Google Scholar
• Smith R, Donald R A., Espiner E A., Stronach S G., Edwards I A. Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-SER(TBU)6-LH-RH-EA10. J Clin Endocrinol Metab 1979; 48: 167–170
   Google Scholar
• Sundaram K, Wang N G., Bardin C W. Antigonadal, antisteroidal, and antifertility effects of LHRH agonists in male animals. LHRH Peptides as Female and Male Contraceptives, G I. Zatuchni, J D. Shelton, J J. Sciarra. Harper & Row, Philadelphia 1981; 361–274
   Google Scholar
• Tcholakian R K., De la Cruz A, Chowdhury M, et al. Unusual anti-reproductive properties of the analog [D-Leu6, des-Gly-NH210] LHRH ethylamidein male rats. Fertil Steril 1978; 30: 600–603
   Google Scholar
• Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas A TA, Comaru-Schally A M., Schally A V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982; 79: 1658–1662
   PubMed Web of Science ®Google Scholar
• Tolis G, Koutsilieris M, Herrera R, Stellow A, Martinez A, Dufresne M. Advanced prostatic carcinoma: Biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH. Med Oncol Tumor Pharmacother 1984; 1: 129–136
   Google Scholar
• Tolis G, Mehta A, Comaru-Schally A M., Schally A V. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest 1981; 68: 819–822
   PubMed Web of Science ®Google Scholar
• Trachtenberg J. The treatment of metastatic prostatic cancer with a potent LHRH analogue. J Urol 1983; 129: 1149–1152
   Google Scholar
• Vickery B. Physiology and antifertility effects of LHRH and agonistic analogs in male animals. LHRH Peptides as Female and Male Contraceptives, G I. Zatuchni, J D. Shelton, J J. Sciarra. Harper & Row, Philadelphia 1981; 275–290
   Google Scholar
• Vickery B H., McRae G. Effects of continuous treatment with superagonists of LHRH when initiated at different times of the menstrual cycle in female baboons. Int J Fertil 1980a; 25: 171–178
   Google Scholar
• Walker K J., Turkes A O., Nicholson R I., Turkes A, Griffiths K. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet 1983; 2: 413–415
   PubMedGoogle Scholar
• Warner B A., Santen R J., Demers L M., Max D T. [D-Leu6 Des-Gly-NH210 Proethylamide9] gonadotropin releasing hormone (leuprolide): A “medical castration” for the treatment of prostatic carcinoma. Clin Res 1981; 29: 666A
   Google Scholar
• Warner B, Santen R, Demers L, et al. Effects of [D-Leu6 DesGlyNH210, Pro-ethylamide9] -GnRH (Leuprolide) on steroidogenesis when used to treat prostatic carcinoma. J Androl 1982; 3: 14
   Google Scholar
• Wenderoth U K., Happ J, Krause U, Adenauer H, Jacobi G H. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients. Eur Urol 1982; 8: 343–347
   Google Scholar
• Wiegelman W, Solbach H G., Kley H K., Nieschlag E, Rudorff K H., Krushkemper H L. A new LHRH analogue [D-Ser(TBU)6 -LHRH-(1–9)-nonapeptide. Hypothalamic Hormone Chemistry, Physiology and Clinical Applications, D Guyta, M Voelter. Verlag Chemie, Weinheim 1978; 327
   Google Scholar